Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inflammatory Determinants of Differential Tuberculosis Risk in Pre-Adolescent Children and Young Adults.
Baguma R, Mbandi SK, Rodo MJ, Erasmus M, Day J, Makhethe L, de Kock M, van Rooyen M, Stone L, Bilek N, Steyn M, Africa H, Darboe F, Chegou NN, Tromp G, Walzl G, Hatherill M, Penn-Nicholson A, Scriba TJ. Baguma R, et al. Among authors: van rooyen m. Front Immunol. 2021 Feb 25;12:639965. doi: 10.3389/fimmu.2021.639965. eCollection 2021. Front Immunol. 2021. PMID: 33717192 Free PMC article.
Application of a whole blood mycobacterial growth inhibition assay to study immunity against Mycobacterium tuberculosis in a high tuberculosis burden population.
Baguma R, Penn-Nicholson A, Smit E, Erasmus M, Day J, Makhethe L, de Kock M, Hughes EJ, van Rooyen M, Pienaar B, Stone L, Hanekom W, Brennan MJ, Wallis RS, Hatherill M, Scriba TJ. Baguma R, et al. Among authors: van rooyen m. PLoS One. 2017 Sep 8;12(9):e0184563. doi: 10.1371/journal.pone.0184563. eCollection 2017. PLoS One. 2017. PMID: 28886145 Free PMC article.
Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy.
Darboe F, Mbandi SK, Naidoo K, Yende-Zuma N, Lewis L, Thompson EG, Duffy FJ, Fisher M, Filander E, van Rooyen M, Bilek N, Mabwe S, McKinnon LR, Chegou N, Loxton A, Walzl G, Tromp G, Padayatchi N, Govender D, Hatherill M, Karim SA, Zak DE, Penn-Nicholson A, Scriba TJ; SATVI Clinical Immunology Team. Darboe F, et al. Among authors: van rooyen m. Front Microbiol. 2019 Jun 26;10:1441. doi: 10.3389/fmicb.2019.01441. eCollection 2019. Front Microbiol. 2019. PMID: 31297103 Free PMC article.
Maturation of innate responses to mycobacteria over the first nine months of life.
Shey MS, Nemes E, Whatney W, de Kock M, Africa H, Barnard C, van Rooyen M, Stone L, Riou C, Kollmann T, Hawn TR, Scriba TJ, Hanekom WA. Shey MS, et al. Among authors: van rooyen m. J Immunol. 2014 May 15;192(10):4833-43. doi: 10.4049/jimmunol.1400062. Epub 2014 Apr 14. J Immunol. 2014. PMID: 24733845 Free PMC article. Clinical Trial.
Diagnostic performance of an optimized transcriptomic signature of risk of tuberculosis in cryopreserved peripheral blood mononuclear cells.
Darboe F, Mbandi SK, Thompson EG, Fisher M, Rodo M, van Rooyen M, Filander E, Bilek N, Mabwe S, Hatherill M, Zak DE, Penn-Nicholson A, Scriba TJ; SATVI Clinical Immunology Team. Darboe F, et al. Among authors: van rooyen m. Tuberculosis (Edinb). 2018 Jan;108:124-126. doi: 10.1016/j.tube.2017.11.001. Epub 2017 Nov 6. Tuberculosis (Edinb). 2018. PMID: 29523312 No abstract available.
RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response.
Penn-Nicholson A, Mbandi SK, Thompson E, Mendelsohn SC, Suliman S, Chegou NN, Malherbe ST, Darboe F, Erasmus M, Hanekom WA, Bilek N, Fisher M, Kaufmann SHE, Winter J, Murphy M, Wood R, Morrow C, Van Rhijn I, Moody B, Murray M, Andrade BB, Sterling TR, Sutherland J, Naidoo K, Padayatchi N, Walzl G, Hatherill M, Zak D, Scriba TJ; Adolescent Cohort Study team; GC6-74 Consortium; SATVI Clinical and Laboratory Team; ScreenTB Consortium; AE-TBC Consortium; RePORT Brazil Team; Peruvian Household Contacts Cohort Team; CAPRISA IMPRESS team. Penn-Nicholson A, et al. Sci Rep. 2020 May 25;10(1):8629. doi: 10.1038/s41598-020-65043-8. Sci Rep. 2020. PMID: 32451443 Free PMC article.
Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults.
Day CL, Tameris M, Mansoor N, van Rooyen M, de Kock M, Geldenhuys H, Erasmus M, Makhethe L, Hughes EJ, Gelderbloem S, Bollaerts A, Bourguignon P, Cohen J, Demoitié MA, Mettens P, Moris P, Sadoff JC, Hawkridge A, Hussey GD, Mahomed H, Ofori-Anyinam O, Hanekom WA. Day CL, et al. Among authors: van rooyen m. Am J Respir Crit Care Med. 2013 Aug 15;188(4):492-502. doi: 10.1164/rccm.201208-1385OC. Am J Respir Crit Care Med. 2013. PMID: 23306546 Free PMC article. Clinical Trial.
The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.
Geldenhuys H, Mearns H, Miles DJ, Tameris M, Hokey D, Shi Z, Bennett S, Andersen P, Kromann I, Hoff ST, Hanekom WA, Mahomed H, Hatherill M, Scriba TJ; H4:IC31 Trial Study Group; van Rooyen M, Bruce McClain J, Ryall R, de Bruyn G; H4:IC31 Trial Study Groupa. Geldenhuys H, et al. Among authors: van rooyen m. Vaccine. 2015 Jul 9;33(30):3592-9. doi: 10.1016/j.vaccine.2015.05.036. Epub 2015 Jun 3. Vaccine. 2015. PMID: 26048780 Clinical Trial.
116 results